This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): Ganciclovir sodium, Cymevene (EU)
Description: Cytovene IV is an acyclic nucleoside analogue of 2'-deoxyguanosine that inhibits replication of the herpes virus. To achieve anti-CMV activity, Cytovene IV is phosphorylated first to the monophosphate form by a CMV-encoded (UL97 gene) protein kinase homologue, then to the di- and triphosphate forms by cellular kinases. Ganciclovir triphosphate is believed to inhibit viral DNA synthesis by competitive inhibition of viral DNA polymerases and incorporation into viral DNA, resulting in eventual termination of viral DNA elongation.
Cytovene IV was previously available in an oral form, but that formulation was discontinued on June 22, 2005.
Cytovene IV News
Pink Sheet Roche Cytovene I.V. shortage lengthens
Additional information available to subscribers only: